RU2009117701A - Производные пирролидина в качестве ингибиторов iap - Google Patents

Производные пирролидина в качестве ингибиторов iap Download PDF

Info

Publication number
RU2009117701A
RU2009117701A RU2009117701/04A RU2009117701A RU2009117701A RU 2009117701 A RU2009117701 A RU 2009117701A RU 2009117701/04 A RU2009117701/04 A RU 2009117701/04A RU 2009117701 A RU2009117701 A RU 2009117701A RU 2009117701 A RU2009117701 A RU 2009117701A
Authority
RU
Russia
Prior art keywords
methylaminopropionamide
pyrrolidin
cyclohexyl
oxoethyl
alkyl
Prior art date
Application number
RU2009117701/04A
Other languages
English (en)
Russian (ru)
Inventor
Марк Г. ЧАРЕСТ (US)
Марк Г. Чарест
Кристине Сютун ЧЭНЬ (US)
Кристине Сютун Чэнь
Мин ЧЭНЬ (US)
Мин Чэнь
Чжуолян ЧЭНЬ (US)
Чжуолян Чэнь
Миао ДАЙ (US)
Миао Дай
Фэн ХЕ (US)
Фэн ХЕ
Хуаншу ЛЕЙ (US)
Хуаншу ЛЕЙ
Кристофер СТРАУБ (US)
Кристофер СТРАУБ
Руньмин Дейвид ВАН (US)
Руньмин Дейвид Ван
Лей ЗАУЭЛ (US)
Лей ЗАУЭЛ
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2009117701A publication Critical patent/RU2009117701A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2009117701/04A 2006-10-12 2007-10-10 Производные пирролидина в качестве ингибиторов iap RU2009117701A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82923406P 2006-10-12 2006-10-12
US60/829,234 2006-10-12

Publications (1)

Publication Number Publication Date
RU2009117701A true RU2009117701A (ru) 2010-11-20

Family

ID=38984426

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009117701/04A RU2009117701A (ru) 2006-10-12 2007-10-10 Производные пирролидина в качестве ингибиторов iap

Country Status (11)

Country Link
US (1) US8044209B2 (enExample)
EP (1) EP2102229B1 (enExample)
JP (1) JP5190062B2 (enExample)
KR (1) KR20090065548A (enExample)
CN (1) CN101595121A (enExample)
AU (1) AU2007307763A1 (enExample)
BR (1) BRPI0719221A2 (enExample)
CA (1) CA2666112A1 (enExample)
MX (1) MX2009003834A (enExample)
RU (1) RU2009117701A (enExample)
WO (1) WO2008045905A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Iap의 피롤리딘 억제제
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
RU2418807C2 (ru) 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
RU2451025C2 (ru) 2005-12-19 2012-05-20 Дженентек, Инк. Ингибиторы iap
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
RU2466131C2 (ru) * 2006-12-19 2012-11-10 Дженентек, Инк. Имидазопиридиновые ингибиторы iap
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
WO2009140447A1 (en) * 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
NZ601483A (en) * 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2012500272A (ja) * 2008-08-16 2012-01-05 ジェネンテック, インコーポレイテッド Iapのアザインドールインヒビター
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
AR077688A1 (es) 2009-08-04 2011-09-14 Takeda Pharmaceutical Compuestos heterociclicos, utiles en el tratamiento de cancer
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
PT2611797T (pt) * 2010-08-31 2017-02-07 Hanmi Science Co Ltd Derivados de quinolina ou de quinazolina com atividade indutora de apoptose nas células
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CN103261186A (zh) * 2010-12-13 2013-08-21 诺瓦提斯公司 二聚化iap抑制剂
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Gpr119作動薬
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
JP2014521651A (ja) * 2011-07-28 2014-08-28 シーエイチディーアイ ファウンデーション,インコーポレーテッド 特定のキヌレニン−3−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NO2755614T3 (enExample) * 2012-01-03 2018-03-31
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
JP6321020B2 (ja) * 2012-10-19 2018-05-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
KR20170004160A (ko) * 2015-07-01 2017-01-11 엘지전자 주식회사 이동단말기 및 그 제어방법
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
IL274598B2 (en) 2017-11-13 2025-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd SMAC mimetics used as IAP inhibitors and their use
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
WO2020177765A1 (zh) * 2019-03-07 2020-09-10 正大天晴药业集团股份有限公司 Iap抑制剂与免疫检查点抑制剂的组合
JP7587526B2 (ja) * 2019-05-10 2024-11-20 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Iap阻害剤としてのsmac模倣物の結晶及びその製造方法
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283827A2 (en) 2000-05-23 2003-02-19 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7718600B2 (en) * 2000-09-29 2010-05-18 The Trustees Of Princeton University IAP binding compounds
CN100384819C (zh) 2002-07-02 2008-04-30 诺瓦提斯公司 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
CA2570321C (en) 2004-07-02 2013-10-08 Genentech, Inc. Inhibitors of iap
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Iap의 피롤리딘 억제제
RU2451025C2 (ru) * 2005-12-19 2012-05-20 Дженентек, Инк. Ингибиторы iap

Also Published As

Publication number Publication date
US8044209B2 (en) 2011-10-25
EP2102229A1 (en) 2009-09-23
JP5190062B2 (ja) 2013-04-24
WO2008045905A1 (en) 2008-04-17
MX2009003834A (es) 2009-04-22
AU2007307763A1 (en) 2008-04-17
BRPI0719221A2 (pt) 2014-03-18
KR20090065548A (ko) 2009-06-22
CA2666112A1 (en) 2008-04-17
CN101595121A (zh) 2009-12-02
US20110015232A1 (en) 2011-01-20
JP2010506847A (ja) 2010-03-04
EP2102229B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
ES2789331T3 (es) Inhibidores de TGF-beta
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
RU2485115C2 (ru) Производные пиримидина в качестве ингибиторов alk-5
ES2501594T3 (es) Composición farmacéutica que contiene un modulador heterocíclico de transportadores de casete de unión a ATP
JP6342393B2 (ja) 置換型ピラゾロン化合物及び使用方法
AR087355A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
HRP20120379T1 (hr) Triheterociklički spojevi, pripravci i postupci za liječenje karcinoma
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
CA3059943A1 (en) K-ras modulators
JP2008525417A5 (enExample)
PE20030007A1 (es) Inhibidores de aldosa reductasa del grupo de las piridazinonas
AR057786A2 (es) Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
ZA200503841B (en) Combination administration of an indolinone with achemotherapeutic agent for cell proliferation dis orders
AR054799A1 (es) Derivados de oxindol
ES2370536T3 (es) 6-oxo-1,6-dihidropirimidín-2-ils en el tratamiento de enfermedades proliferativas.
AR041739A1 (es) Compuestos derivados -3,4-dihidro-1h-pirimido[4,5-d]pirimidin-2-ona y con actividad antiproliferativa.
RU2009113691A (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ ГИДРОЛИЗА АТФ, СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ В-КЛЕТОК, СПОСОБ ОПРЕДЕЛЕНИЯ Btk В ОБРАЗЦЕ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ВОСПРИИМЧИВЫХ К ИНГИБИРОВАНИЮ АКТИВНОСТИ Btk И СПОСОБ ПОВЫШЕНИЯ ЧУВСТВИТЕЛЬНОСТИ РАКОВЫХ КЛЕТОК К ХИМИОТЕРАПИИ
RU2014120166A (ru) Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
PT2578571E (pt) Moduladores de transportadores de atp-binding cassette
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110314